Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $8.00

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given a consensus rating of “Hold” by the six analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.00.

A number of equities research analysts recently issued reports on the company. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Zacks Research downgraded Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Wells Fargo & Company upped their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th.

Insiders Place Their Bets

In other Milestone Pharmaceuticals news, insider David Bharucha sold 58,007 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total value of $134,576.24. Following the completion of the sale, the insider owned 91,993 shares in the company, valued at $213,423.76. The trade was a 38.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jeffrey Edward Nelson sold 58,007 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the sale, the chief operating officer owned 41,993 shares of the company’s stock, valued at approximately $97,423.76. The trade was a 58.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 416,327 shares of company stock valued at $935,458 in the last quarter. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently bought and sold shares of MIST. Propel Bio Management LLC boosted its position in shares of Milestone Pharmaceuticals by 186.1% in the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after buying an additional 3,333,333 shares during the period. Orbimed Advisors LLC acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth $6,444,000. Simplify Asset Management Inc. lifted its position in shares of Milestone Pharmaceuticals by 186.2% during the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Milestone Pharmaceuticals by 289.8% in the fourth quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after purchasing an additional 1,231,793 shares during the period. Finally, Pathstone Holdings LLC acquired a new stake in Milestone Pharmaceuticals during the 3rd quarter valued at $2,000,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.58 on Thursday. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The company has a market cap of $134.57 million, a price-to-earnings ratio of -1.93 and a beta of 0.48. The firm has a 50 day moving average of $1.87 and a 200-day moving average of $2.00. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.